Fibrilação Atrial – diagnóstico, fisiopatologia e terapêutica
Palavras-chave:
fibrilação atrial, tratamento, ablaçãoResumo
A fibrilação atrial é uma arritmia cardíaca muito frequente, com morbidade e mortalidade elevadas, e sua prevalência mundial está aumentando significativamente. O tratamento envolve múltiplas abordagens farmacológicas, porém frequentemente requer tratamento invasivo por ablação para o controle clínico. Este artigo resume o conhecimento atual sobre a fibrilação atrial, enfatizando o tratamento baseado em sua complexa fisiopatologia.
Referências
Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation. Hear Rhythm. 2017;(May):1. doi:10.1016/j.hrthm.2017.05.012
Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol. 2014. doi:10.2147/CLEP.S47385
Patel NJ, Deshmukh A, Pant S, et al. Contemporary trends of hospitalization for atrial fibrillation in the united states, 2000 through 2010 implications for healthcare planning. Circulation. 2014. doi:10.1161/CIRCULATIONAHA.114.008201
Magalhães L, Figueiredo M, Cintra F, et al. II Diretrizes Brasileiras de Fibrilação Atrial. Arq Bras Cardiol. 2016;106(4):1-22. doi:10.5935/abc.20160055
Haïssaguerre M, Jaïs P, Shah DC, et al. Spontaneous Initiation of Atrial Fibrillation by Ectopic Beats Originating in the Pulmonary Veins. N Engl J Med. 1998;339(10):659-666. doi:10.1056/NEJM199809033391003
Marrouche NF, Wilber D, Hindricks G, et al. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. JAMA. 2014;311(5):498-506. doi:10.1001/jama.2014.3
Wijffels MCEF, Kirchhof CJHJ, Dorland R, Allessie MA. Atrial Fibrillation Begets Atrial Fibrillation. Circulation. 1995;92(7):1954-1968. doi:10.1161/01.CIR.92.7.1954
Rodriguez LM, Timmermans C, Wellens HJJ. Are Electrophysiological Changes Induced by Longer Lasting Atrial Fibrillation Reversible? Circulation. 1999;100(2):113-116. doi:10.1161/01.CIR.100.2.113
Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994. doi:10.1001/jama.1994.03510350050036
Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: The Framingham heart study. Circulation. 2003. doi:10.1161/01.CIR.0000072767.89944.6E
Gami AS, Hodge DO, Herges RM, et al. Obstructive Sleep Apnea, Obesity, and the Risk of Incident Atrial Fibrillation. J Am Coll Cardiol. 2007. doi:10.1016/j.jacc.2006.08.060
Frost L, Hune LJ, Vestergaard P. Overweight and obesity as risk factors for atrial fibrillation or flutter: The Danish Diet, Cancer, and Health Study. Am J Med. 2005. doi:10.1016/j.amjmed.2005.01.031
Conen D, Tedrow UB, Cook NR, Moorthy M V, Buring JE, Albert CM. Alcohol consumption and risk of incident atrial fibrillation in women. JAMA. 2008. doi:10.1001/jama.2008.755
Lubitz SA, Yin X, Fontes JD, et al. Association between familial atrial fibrillation and risk of new-onset atrial fibrillation. JAMA. 2010. doi:10.1001/jama.2010.1690
Ellinor PT, Lunetta KL, Albert CM, et al. Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet. 2012. doi:10.1038/ng.2261.Meta-analysis
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991. doi:10.1161/01.STR.22.8.983
Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA. 2003. doi:10.1016/j.accreview.2003.09.035
Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857-867. doi:10.7326/0003-4819-146-12-200706190-00007
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009. doi:10.1056/NEJMoa0905561
Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011. doi:10.1056/NEJMoa1009638
Granger CB, Alexander JH, McMurray JJ V, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011. doi:10.1056/NEJMoa1411087
Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2013. doi:10.1056/NEJMoa1310907
Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. EP Eur. 2018;20(1):e1-e160. doi:10.1093/europace/eux274
Zhang LT, Gay M. Characterizing left atrial appendage functions in sinus rhythm and atrial fibrillation using computational models. J Biomech. 2008;41(11):2515-2523. doi:10.1016/j.jbiomech.2008.05.012
Reddy VY, Sievert H, Halperin J, et al. Percutaneous Left Atrial Appendage Closure vs Warfarin for Atrial Fibrillation. JAMA. 2014;312(19):1988-1998. doi:10.1001/jama.2014.15192
Osmancik P, Herman D, Neuzil P, et al. Left Atrial Appendage Occlusion Versus Direct Oral Anticoagulants in High-Risk Patients with Atrial Fibrillation. J Am Coll Cardiol 2020; 75: 3122-3135 doi 10.1016/j.jacc.2020.04.067
